In the STEP 1 trial, once-weekly 2.4mg semaglutide produced a mean 14.9% body-weight reduction over 68 weeks establishing GLP-1 agonism as a leading anti-obesity mechanism
**Based on a 6-month clinical trial (n=180) of individuals who were enrolled between FebruaryApril 2024, with overweight or obesity taking semaglutide or tirzepatide for weight loss and related outcomes through the WW Clinic Program and participating in the GLP-1 companion nutrition program
Focus on consistency rather than intensitymovement should energize you, not exhaust you
Mild reactions often resolve with supportive care
Hauner H, Glatting G, Kaminska D, Pfeiffer EF
It tends to mobilize peripheral fat first while protecting visceral and abdominal stores, which is exactly where the health risks of obesity are concentrated